<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02514850</url>
  </required_header>
  <id_info>
    <org_study_id>BC3-CT018</org_study_id>
    <nct_id>NCT02514850</nct_id>
  </id_info>
  <brief_title>A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes</brief_title>
  <official_title>A Randomised, Single Dose, Double-blind, Double-dummy, Three-period Cross-over Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adocia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adocia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single centre, randomised, double-blind, double-dummy, 3-treatment, 3-period
      cross-over, euglycaemic clamp study in subjects with type 2 diabetes on stable insulin
      treatment. Each subject will be randomly allocated to a treatment sequence and will be
      administered single subcutaneous doses of 0.8 U/kg Biochaperone® Combo, 0.8 U/kg Humalog®
      Mix25 or simultaneous subcutaneous injections of 0.2 U/kg Humalog® and 0.6 U/kg Lantus®
      during three separate dosing visits.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the glucose infusion rate curve (AUCGIR) 12-30h (mg/kg)</measure>
    <time_frame>from 12h to 30 hours</time_frame>
    <description>Area under the glucose infusion rate curve from 12 hours to 30 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCGIR 0-last (mg/kg)</measure>
    <time_frame>Up to 30 hours</time_frame>
    <description>Area under the glucose infusion rate curve from 0 hours until the end of clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GIRmax (mg/kg/min)</measure>
    <time_frame>Up to 30 hours</time_frame>
    <description>Maximum glucose infusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tGIRmax</measure>
    <time_frame>Up to 30 hours</time_frame>
    <description>Time to maximum glucose infusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCLis 0-30h</measure>
    <time_frame>Up to 30 hours</time_frame>
    <description>Area under the insulin lispro plasma concentration time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCGla 0-30h</measure>
    <time_frame>Up to 30 hours</time_frame>
    <description>Area under the insulin glargine plasma concentration time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax Gla</measure>
    <time_frame>Up to 30 hours</time_frame>
    <description>Time to maximum insulin glargine plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax Lis</measure>
    <time_frame>Up to 30 hours</time_frame>
    <description>Time to maximum insulin lispro plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 9 weeks</time_frame>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycaemic episodes</measure>
    <time_frame>Up to 9 weeks</time_frame>
    <description>Number of Hypoglycaemic episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local tolerability</measure>
    <time_frame>Up to 9 weeks</time_frame>
    <description>Number and intensity of injection site reactions</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Biochaperone Combo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single subcutaneous injection of 0.8 U/kg + injection of placebo (0.9% NaCl) to ensure the double dummy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humalog Mix25</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single subcutaneous dose of 0.8 U/kg + injection of placebo (0.9% NaCl) to ensure the double dummy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humalog and Lantus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>simultaneous subcutaneous injections of 0.2 U/kg Humalog and 0.6 U/kg Lantus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biochaperone Combo</intervention_name>
    <description>Injection of BioChaperone Combo</description>
    <arm_group_label>Biochaperone Combo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humalog Mix25</intervention_name>
    <description>Injection of Humalog Mix25</description>
    <arm_group_label>Humalog Mix25</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humalog</intervention_name>
    <description>Injection of Humalog</description>
    <arm_group_label>Humalog and Lantus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lantus</intervention_name>
    <description>Injection of Lantus</description>
    <arm_group_label>Humalog and Lantus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Injection of saline 0.9% solution</description>
    <arm_group_label>Biochaperone Combo</arm_group_label>
    <arm_group_label>Humalog Mix25</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus (as diagnosed clinically) for ≥ 12 months

          -  HbA1c levels ≤ 9.0%

          -  Total insulin dose of &lt; 1.2 U/kg/day

          -  Body mass index between 20.0 and 35.0 kg/m2 (both inclusive)

          -  Body weight ≤ 125.0 kg

          -  Fasting serum C-peptide ≤ 1 nmol/L

          -  Treated with a stable insulin regimen for ≥ 3 months prior to screening

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Known or suspected allergy to the trial products or related products

          -  Previous participation in this trial. Participation is defined as randomised

          -  Participation in any clinical trial within 3 months prior to this trial

          -  Clinically significant abnormal haematology, biochemistry, lipids, or urinalysis
             screening tests, as judged by the Investigator considering the underlying disease

          -  Supine blood pressure at screening outside the range of 90-160 mmHg for systolic or
             50-95 mmHg for diastolic and/or resting supine heart rate outside the range 50 -90
             beats per minute. This exclusion criterion also pertains to subjects being on
             antihypertensives

          -  Use of GLP-1 receptor agonists or oral antidiabetic drugs (OADs) other than stable
             intake of metformin within 4 weeks prior to screening

          -  Women of child bearing potential, not willing to use contraceptive methods
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrike Hövelmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut Für Stoffwechselfforschung GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2015</study_first_submitted>
  <study_first_submitted_qc>July 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2015</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

